Abstract: A method for determining a state of a cell, the cell being placed in a sample in contact with a culture medium, includes illuminating the sample with a light source and acquiring an image of the sample with an image sensor, the image sensor lying in a detection plane. From the acquired image, a position of the cell in a plane parallel to the detection plane is located and a refractive index or a relative refractive index of the cell is estimated, the relative refractive index corresponding to a refractive index of the cell relative to the refractive index of the culture medium. From the estimation, an index of interest of the cell is determined. From the index, a state of the cell among predetermined states is classified, the predetermined states including at least one apoptosis state and one living state.

Abstract: A modular production system including a plurality of production modules connected in a linear series to form a production tunnel, and collectively defining a production channel, and wherein at least one fluid inlet port defined along the production tunnel, said inlet port is in fluid communication with a pressurized fluid source, whereby influx of fluid from said fluid source through said fluid inlet port acts to maintain the fluid pressure within the production channel at a higher pressure than the atmospheric pressure outside of the production tunnel; and wherein one of said production modules positioned between said proximal-most and distal-most production modules comprises a depyrogenator and/or sterilization module, comprising a transparent tubular body, and an irradiation source positioned external to said transparent tubular body, said irradiation source capable of heating the internal environment of the depyrogenation and/or sterilization module to a temperature sufficient to depyrogenate or sterilize

Abstract: The invention relates to compounds of Formula (I), (Ia), (II) or (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.

Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

Abstract: Provided are compounds and pharmaceutical compositions and uses thereof for inhibiting Nav1.8 voltage-gated sodium ion channels and treating Nav1.8 mediated diseases, such as pain and pain-associated diseases, and cardiovascular diseases.

Abstract: The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.

Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGF? inhibitor, and a TIGIT inhibitor to treat cancer.

Abstract: The present invention relates generally to antibodies in the treatment of human disease and reduction of adverse events related thereto. More specifically, the present invention relates to the use of IL 1RAP (Interleukin-1 receptor accessory protein) binding proteins (including anti-IL 1RAP 0 antagonist antibodies) and their use as treatment and prevention of human disease.

Abstract: The present disclosure relates to compositions for treating CD96 mediated diseases, and related methods.

Abstract: The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral infection wherein R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y and Z are defined herein.

Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.

Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.

Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGF? inhibitor, an ATM inhibitor and radiation to treat cancer.

Abstract: The present invention relates to a pharmaceutical composition, particularly a pharmaceutical composition comprising an IgG:TGF?RII (such as an anti-PD-L1:TGF?-inhibiting) fusion protein. The present invention also relates inter alia to a method of manufacturing the composition, to a kit including the composition, to a package including the composition, to a method of manufacturing the package, and to methods of treatment using the composition and/or package, especially cancer treatments.

Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.

Abstract: The invention relates to a compound having the structure: or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions and therapeutic methods thereof.

Abstract: The present disclosure provides engineered carboxyesterase enzymes that have the ability to catalyze amide bond formation. Also provided are polynucleotides encoding the carboxyesterase enzymes, host cells capable of expressing the engineered carboxyesterase enzymes, and methods of using the engineered carboxyesterase enzymes to make commercially valuable amides. Also provided are amides that are made using the engineered carboxyesterase enzymes.

Abstract: The present invention relates to a method of purifying a recombinant polypeptide from Host Cell Proteins (HCP), the method comprising: (a) applying a solution comprising the recombinant polypeptide and HCP to a superantigen chromatography solid support, (b) washing the superantigen chromatography solid support with a wash buffer comprising caprylate and arginine; and (c) eluting the recombinant polypeptide from the superantigen chromatography solid support.